title: EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX.
abstract: Latent membrane protein 1 (LMP-1) of Epstein-Barr virus (EBV) promotes tumorigenesis by inhibiting apoptosis. We show that an important antiapoptotic activity of LMP-1 is the inhibition of Bcl2-associated protein X (Bax), a potent proapoptotic protein. BAX expression was regulated by LMP-1 activation of nuclear factor kappaB (NF-kappaB) via the C-terminal activation region 1 (CTAR-1) and CTAR-2. Interestingly, p65/p50 inhibited, whereas p50/p50 increased, BAX promoter activity as demonstrated by overexpression and selective inhibition of these NF-kappaB isoforms. Electrophoretic mobility shift analysis revealed that LMP-1 activates 2 of the 3 NF-kappaB binding sites (kappaB1-kappaB3) in the BAX promoter. LMP-1 induced binding of the NF-kappaB heterodimer p65/p50 to the kappaB2 site and of the p50/p50 homodimer to the kappaB3 site. Promoter mutation analysis revealed that the kappaB2 site is necessary for inhibition of BAX promoter activity and the kappaB3 site, for its activation. However, the activation of the BAX promoter by LMP-1 was observed only in the presence of specific inhibitors of p65/p50. In all other cases, LMP-1 inhibited BAX promoter activity. Most importantly, the antiapoptotic activity of LMP-1 was considerably decreased in cells deficient for BAX. These results indicate that the inhibition of Bax may be an important antiapoptotic activity of LMP-1.
authors.affiliation: University of Erlangen-Nürnberg, Department of Surgery, Division of Molecular and Experimental Surgery, Schwabachanlage 10, D-91054 Erlangen, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Grimm
authors.forename: Sabine
authors.initials: S
authors.lastname: Schneider
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Naschberger
authors.forename: Jürgen
authors.initials: J
authors.lastname: Huber
authors.forename: Eric
authors.initials: E
authors.lastname: Guenzi
authors.forename: Arnd
authors.initials: A
authors.lastname: Kieser
authors.forename: Peter
authors.initials: P
authors.lastname: Reitmeir
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Schulz
authors.forename: Cindy A
authors.initials: CA
authors.lastname: Morris
authors.forename: Michael
authors.initials: M
authors.lastname: Stürzl
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000502:physiology*; D001402:B-Lymphocytes / Q000166:cytology / Q000821:virology*; D016466:CHO Cells; D006224:Cricetinae; D020031:Epstein-Barr Virus Infections / Q000503:physiopathology*; D015967:Gene Expression Regulation, Viral / Q000502:physiology; D006367:HeLa Cells; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D016328:NF-kappa B / Q000378:metabolism; D052002:NF-kappa B p50 Subunit; D011401:Promoter Regions, Genetic / Q000502:physiology; D011498:Protein Precursors / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology; D051996:Transcription Factor RelA; D014763:Viral Matrix Proteins / Q000235:genetics / Q000378:metabolism*; D051028:bcl-2-Associated X Protein
chemical_list: C494826:BAX protein, human; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D016328:NF-kappa B; D052002:NF-kappa B p50 Subunit; D011498:Protein Precursors; D019253:Proto-Oncogene Proteins c-bcl-2; D051996:Transcription Factor RelA; D014763:Viral Matrix Proteins; D051028:bcl-2-Associated X Protein